Abciximab suppresses the rise in levels of circulating inflammatory markers after percutaneous coronary revascularization.
Ray
Kausik K
KK
D000077284:Abciximab; D015906:Angioplasty, Balloon, Coronary / Q000009:adverse effects; D000911:Antibodies, Monoclonal / Q000494:pharmacology*; D015415:Biomarkers / Q000097:blood*; D015986:Confounding Factors, Epidemiologic; D003328:Coronary Thrombosis / Q000209:etiology / Q000517:prevention & control; D006801:Humans; D007140:Immunoglobulin Fab Fragments / Q000494:pharmacology*; D007249:Inflammation / Q000097:blood* / Q000209:etiology; D009203:Myocardial Infarction / Q000209:etiology / Q000517:prevention & control; D010975:Platelet Aggregation Inhibitors / Q000494:pharmacology*; D019039:Platelet Glycoprotein GPIIb-IIIa Complex / Q000037:antagonists & inhibitors; D012306:Risk
D000911:Antibodies, Monoclonal; D015415:Biomarkers; D007140:Immunoglobulin Fab Fragments; D010975:Platelet Aggregation Inhibitors; D019039:Platelet Glycoprotein GPIIb-IIIa Complex; D000077284:Abciximab